Bulletin du cancer
[Zanidatamab in second line setting of advanced HER2-positive biliary tract cancers].
Ingrid Diagne, Matthieu Delaye
Published: 202610.1016/j.bulcan.2025.11.003
No abstract available for this study.
Ingrid Diagne, Matthieu Delaye
No abstract available for this study.